Rajesh C. Shrotriya MD

Rajesh C. Shrotriya MD discloses dealings in Spectrum Pharmaceuticals Inc to SEC (Form 4). Between 1 January 2006 and 17 May 2018, the trades on record add up to 157 filings.

The open-market side counts 12 purchases for €763k alongside 46 sales for €21.0M. On balance, insiders were net sellers of €20.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 62 share grants and 31 option exercises. So far in 2018, the count stands at no purchases and 35 sales.

Half of the purchases are above €14k and half below.

The newest entry dates from 17 May 2018: a transaction, in Spectrum Pharmaceuticals Inc. The most recent open-market purchase was published on 24 June 2010, 5,981 days ago. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.